INVESTIGATOR INITIATED RESEARCH AGREEMENTInvestigator Initiated Research Agreement • September 14th, 2021
THIS INVESTIGATOR INITIATED RESEARCH AGREEMENT (this “Agreement”), is effective as of June 1st, 2021 (the “Effective Date”), by and between:
INVESTIGATOR-INITIATED RESEARCH AGREEMENTInvestigator-Initiated Research Agreement • November 20th, 2015
And each of the following member institutions of The University of Texas System: The University of Texas Health Science Center at San Antonio
INVESTIGATOR INITIATED RESEARCH AGREEMENTInvestigator Initiated Research Agreement • August 29th, 2018
This Investigator Initiated Research Agreement ("Agreement") is made and entered into by and among Amgen s.r.o., Klimentská 1216/46, 110 02 Praha 1, Česká republika ("Company"); Ústav hematologie a krevní transfuze, U Nemocnice 2094/1, 128 20 Praha 2, Česká republika; VAT number 00023736, tax-exempt number CZ00023736, represented by prof. MUDr. Petr Cetkovský, Ph.D., MBA, director (“Sponsor”); and XXXXXXXXXXXXXXXXX, working place: Ústav hematologie a krevní transfuze, U nemocnice 1, 12820, Praha 2, Česká republika; home address: XXXXXXXXXXXXXX; Date of Birth: XXXXXXXXXX
